Compare GSHD & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | ORKA |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2018 | N/A |
| Metric | GSHD | ORKA |
|---|---|---|
| Price | $43.64 | $31.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $90.40 | $52.70 |
| AVG Volume (30 Days) | ★ 627.3K | 295.9K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | N/A |
| Revenue This Year | $16.69 | N/A |
| Revenue Next Year | $19.77 | N/A |
| P/E Ratio | $42.44 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $42.87 | $5.49 |
| 52 Week High | $124.40 | $36.53 |
| Indicator | GSHD | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 43.63 |
| Support Level | $42.87 | $31.43 |
| Resistance Level | $77.70 | $32.46 |
| Average True Range (ATR) | 2.50 | 2.04 |
| MACD | -0.10 | -0.18 |
| Stochastic Oscillator | 4.09 | 8.83 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.